Enhancement of the in vivo persistence and antitumor efficacy of CD19 chimeric antigen receptor T cells through the delivery of modified TERT mRNA

Cell Discovery

Volumn 1, Issue 1, 2015, Pages

  Bai, Yun ^a   Kan, Shifeng ^a   Zhou, Shixin ^a   Wang, Yuting ^a   Xu, Jun ^b   Cooke, John P ^d   Wen, Jinhua ^a   Deng, Hongkui ^a,b,c  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b Peking University   (China)

^c PEKING UNIVERSITY   (China)

^d HOUSTON METHODIST HOSPITAL   (United States)

Author keywords

CD19 CAR T cells; hTERT; modified mRNA

Indexed keywords

EID: 85008465526     PISSN: 20565968     EISSN: 20565968     Source Type: Journal    
DOI: 10.1038/CELLDISC.2015.40     Document Type: Article

References (39)

1. Cheadle EJ, Sheard V, Hombach AA et al. Chimeric antigen receptors for T-cell based therapy. Methods Mol Biol 2012; 907: 645-666.
2. Restifo NP, Dudley ME, Rosenberg SA. Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol 2012; 12: 269-281.
3. Jensen MC, Riddell SR. Designing chimeric antigen receptors to effectively and safely target tumors. Curr Opin Immunol 2015; 33: 9-15.
4. Ramos CA, Dotti G. Chimeric antigen receptor (CAR)-engineered lymphocytes for cancer therapy. Expert Opin Biol Ther 2011; 11: 855-873.
5. Grupp SA, Kalos M, Barrett D et al. Chimeric Antigen receptor-modified T cells for acute lymphoid leukemia. New Engl J Med 2013; 368: 1509-1518.
6. Maude SL, Frey N, Shaw PA et al. chimeric antigen receptor T cells for sustained remissions in leukemia. New Engl J Med 2014; 371: 1507-1517.
7. Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. New Engl J Med 2011; 365: 725-733.
8. Brentjens RJ, Riviere I, Park JH et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood 2011; 118: 4817-4828.
9. Kochenderfer JN, Dudley ME, Feldman SA et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 2012; 119: 2709-2720.
10. Effros RB, Pawelec G. Replicative senescence of T cells: does the Hayflick Limit lead to immune exhaustion? Immunol Today 1997; 18: 450-454.
11. Zhou J, Shen X, Huang J et al. Telomere length of transferred lymphocytes correlates with in vivo persistence and tumor regression in melanoma patients receiving cell transfer therapy. J Immunol 2005; 175: 7046-7052.
12. Milone MC, Fish JD, Carpenito C et al. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol Ther 2009; 17: 1453-1464.
13. Robbins PF, Dudley ME, Wunderlich J et al. Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy. J Immunol 2004; 173: 7125-7130.
14. Shen X, Zhou J, Hathcock KS et al. Persistence of tumor infiltrating lymphocytes in adoptive immunotherapy correlates with telomere length. J Immunother 2007; 30: 123-129.
15. Rubtsova MP, Vasilkova DP, Malyavko AN et al. Telomere lengthening and other functions of telomerase. Acta Naturae 2012; 4: 44-61.
16. Migliaccio M, Amacker M, Just T et al. Ectopic human telomerase catalytic subunit expression maintains telomere length but is not sufficient for CD8+ T lymphocyte immortalization. J Immunol 2000; 165: 4978-4984.
17. Rufer N, Migliaccio M, Antonchuk J et al. Transfer of the human telomerase reverse transcriptase (TERT) gene into T lymphocytes results in extension of replicative potential. Blood 2001; 98: 597-603.
18. Josephson K, Ricardo A, Szostak JW. mRNA display: from basic principles to macrocycle drug discovery. Drug Discov Today 2014; 19: 388-399.
19. Bernal JA. RNA-based tools for nuclear reprogramming and lineage-conversion: towards clinical applications. J Cardiovasc Transl Res 2013; 6: 956-968.
20. Zangi L, Lui KO, von Gise A et al. ModifiedmRNA directs the fate of heart progenitor cells and induces vascular regeneration after myocardial infarction. Nat Biotechnol 2013; 31: 898-907.
21. Hansson ML, Albert S, Gonzalez SL et al. Efficient delivery and functional expression of transfected modified mRNA in human embryonic stem cell-derived retinal pigmented epithelial cells. J Biol Chem 2015; 290: 5661-5672.
22. Warren L, Manos PD, Ahfeldt T et al. Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. Cell Stem Cell 2010; 7: 618-630.
23. Ramunas J, Yakubov E, Brady JJ et al. Transient delivery of modified mRNA encoding TERT rapidly extends telomeres in human cells. FASEB J 2015; 29: 1930-1939.
24. Barrett DM, Zhao Y, Liu X et al. Treatment of advanced leukemia in mice with mRNA engineered T cells. Hum Gene Ther 2011; 22: 1575-1586.
25. Jensen MC, Popplewell L, Cooper LJ et al. Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans. Biol Blood Marrow Transplant 2010; 16: 1245-1256.
26. Song DG, Ye Q, Carpenito C et al. In vivo persistence, tumor localization, and antitumor activity of CARengineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB). Cancer Res 2011; 71: 4617-4627.
27. Hooijberg E, Ruizendaal JJ, Snijders PJF et al. Immortalization of human CD8+ T cell clones by ectopic expression of telomerase reverse transcriptase. J Immunol 2000; 165: 4239-4245.
28. Bennaceur K, Atwill M, Al ZN et al. Atorvastatin induces T cell proliferation by a telomerase reverse transcriptase (TERT) mediated mechanism. Atherosclerosis 2014; 236: 312-320.
29. Verra NC, Jorritsma A, Weijer K et al. Human telomerase reverse transcriptase-transduced human cytotoxic T cells suppress the growth of human melanoma in immunodeficient mice. Cancer Res 2004; 64: 2153-2161.
30. Barsov EV. Telomerase and primary T cells: biology and immortalization for adoptive immunotherapy. Immunotherapy 2011; 3: 407-421.
31. Brentjens RJ, Davila ML, Riviere I et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med 2013; 5: 138r-177r.
32. Davila ML, Riviere I, Wang X et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med 2014; 6: 224r-225r.
33. Imai C, Mihara K, Andreansky M et al. Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia. Leukemia 2004; 18: 676-684.
34. Kowolik CM, Topp MS, Gonzalez S et al. CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells. Cancer Res 2006; 66: 10995-11004.
35. Ahmed N, Brawley VS, Hegde M et al. Human epidermal growth factor receptor 2 (HER2) -specific chimeric antigen receptor-modified T cells for the immunotherapy of HER2-positive sarcoma. J Clin Oncol 2015; 33: 1688-1696.
36. Chen Z. Clinical application of adoptive T cell therapy in solid tumors. Med Sci Monit 2014; 20: 953-959.
37. Kakarla S, Gottschalk S. CAR T cells for solid tumors: armed and ready to go? Cancer J 2014; 20: 151-155.
38. Kalos M, Levine BL, Porter DL et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 2011; 3: 73r-95r.
39. Beniumovich MS. Determination of the time for population doubling in monolayer cultures. Biull Eksp Biol Med 1966; 62: 120-123.